Cargando…
芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501287/ https://www.ncbi.nlm.nih.gov/pubmed/34547879 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.08.015 |
| _version_ | 1784580648059535360 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8501287 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Editorial office of Chinese Journal of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85012872021-10-15 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 Zhonghua Xue Ye Xue Za Zhi 病例报告 Editorial office of Chinese Journal of Hematology 2021-08 /pmc/articles/PMC8501287/ /pubmed/34547879 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.08.015 Text en 2021年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
| spellingShingle | 病例报告 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| title | 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| title_full | 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| title_fullStr | 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| title_full_unstemmed | 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| title_short | 芦可替尼治疗PCM1-JAK2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| title_sort | 芦可替尼治疗pcm1-jak2融合基因阳性骨髓增殖性肿瘤伴嗜酸性粒细胞增多症一例 |
| topic | 病例报告 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501287/ https://www.ncbi.nlm.nih.gov/pubmed/34547879 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.08.015 |
| work_keys_str_mv | AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì AT lúkětìnízhìliáopcm1jak2rónghéjīyīnyángxìnggǔsuǐzēngzhíxìngzhǒngliúbànshìsuānxìnglìxìbāozēngduōzhèngyīlì |